Marc Goodman
Stock Analyst at Leerink Partners
(3.61)
# 803
Out of 5,147 analysts
94
Total ratings
57.33%
Success rate
22.09%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANE Veradermics | Initiates: Outperform | $75 | $45.85 | +63.58% | 1 | Mar 2, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $150 → $205 | $163.89 | +25.08% | 8 | Jan 28, 2026 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | $8 | $3.49 | +129.23% | 1 | Jan 12, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Outperform | $30 | $17.27 | +73.71% | 1 | Nov 21, 2025 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $5 | $1.63 | +206.75% | 1 | Nov 17, 2025 | |
| LBRX LB Pharmaceuticals | Initiates: Outperform | $34 | $24.01 | +41.61% | 1 | Oct 6, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $60 → $50 | $11.52 | +334.03% | 7 | Aug 12, 2025 | |
| AMLX Amylyx Pharmaceuticals | Upgrades: Outperform | $4 → $10 | $15.17 | -34.08% | 5 | May 7, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $4.56 | -78.07% | 3 | Dec 4, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $13.49 | +137.21% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $190.30 | -86.86% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $21.18 | +136.07% | 1 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $4.30 | +365.12% | 3 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $100 → $115 | $132.25 | -13.04% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $191.82 | +61.61% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $43.23 | +6.41% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $24.56 | -14.50% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $190.02 | +10.51% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.93 | +241.30% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $30.10 | -10.30% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $5.46 | +174.73% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $684.79 | -60.57% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $232.08 | -58.63% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $62.37 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $123.82 | -45.89% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $13.22 | +641.30% | 7 | Oct 5, 2017 |
Veradermics
Mar 2, 2026
Initiates: Outperform
Price Target: $75
Current: $45.85
Upside: +63.58%
Axsome Therapeutics
Jan 28, 2026
Maintains: Outperform
Price Target: $150 → $205
Current: $163.89
Upside: +25.08%
Neumora Therapeutics
Jan 12, 2026
Initiates: Outperform
Price Target: $8
Current: $3.49
Upside: +129.23%
MapLight Therapeutics
Nov 21, 2025
Initiates: Outperform
Price Target: $30
Current: $17.27
Upside: +73.71%
Ovid Therapeutics
Nov 17, 2025
Initiates: Outperform
Price Target: $5
Current: $1.63
Upside: +206.75%
LB Pharmaceuticals
Oct 6, 2025
Initiates: Outperform
Price Target: $34
Current: $24.01
Upside: +41.61%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $60 → $50
Current: $11.52
Upside: +334.03%
Amylyx Pharmaceuticals
May 7, 2025
Upgrades: Outperform
Price Target: $4 → $10
Current: $15.17
Upside: -34.08%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $4.56
Upside: -78.07%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $13.49
Upside: +137.21%
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $190.30
Upside: -86.86%
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $21.18
Upside: +136.07%
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $4.30
Upside: +365.12%
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $132.25
Upside: -13.04%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $191.82
Upside: +61.61%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $43.23
Upside: +6.41%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $24.56
Upside: -14.50%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $190.02
Upside: +10.51%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.93
Upside: +241.30%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $30.10
Upside: -10.30%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $5.46
Upside: +174.73%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $684.79
Upside: -60.57%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $232.08
Upside: -58.63%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $62.37
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $123.82
Upside: -45.89%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $13.22
Upside: +641.30%